FirstHealth of the Carolinas

Clinical Trial Details

Study Title: GOG 258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Study Type: Interventional
Study Condition: Endometrial Cancer
Investigator: Dr. John Byron
Phone: (910) 692-7928
Research Coordinator: Pam Mason
Phone: (910) 715-2200
Eligibility Criteria: Women, ages 18 years or older, with confirmed endometrial cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Gynecologic Oncology Group
Study Rationale: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether carboplatin and paclitaxel are more effective with or without cisplatin and radiation therapy in treating patients with endometrial cancer.
Study Purpose: This randomized phase III trial is studying carboplatin and paclitaxel to see how well they work when given with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer.
Study Link: http://clinicaltrials.gov/show/NCT00942357
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.